Le chiffre qui pourrait prédire le succès du traitement du cancer
Une étude portant sur près de 4 900 patients atteints d’un cancer de la prostate métastatique a révélé que les patients dont le taux de PSA est descendu en dessous de 0,2 en neuf mois…
Évaluation
A large study of nearly 4,900 metastatic prostate cancer patients found that those whose PSA levels dropped below 0.2 within nine months had a 54 percent lower risk of death. The researchers caution that the rate of decline alone is not always sufficient to gauge treatment success. This suggests that while early PSA suppression is a strong prognostic signal, clinicians will need to integrate it with other factors. The finding could reshape how treatment efficacy is measured in advanced prostate cancer.